Recent advances in understanding the pathogenesis of scleroderma- interstitial lung disease

Current Rheumatology Reports

Volumn 16, Issue 4, 2014, Pages

  Akter, Tanjina ^a   Silver, Richard M ^a   Bogatkevich, Galina S ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Epigenetics; Fibroblast, TGF ; Genetics; Interstitial lung disease (ILD); Pathogenesis; Scleroderma; Systemic sclerosis (SSc); Thrombin; Wnt catenin pathway

Indexed keywords

BETA CATENIN; CONNECTIVE TISSUE GROWTH FACTOR; HLA DPB1 ANTIGEN; HLA DRB1 ANTIGEN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 1; STAT4 PROTEIN; THROMBIN; TRANSCRIPTION FACTOR T BET; TRANSFORMING GROWTH FACTOR BETA; WNT PROTEIN; CTNNB1 PROTEIN, HUMAN; HLA D ANTIGEN;

ARTICLE; CD226 GENE; CTGF GENE; EPIGENETICS; FIBROBLAST; GENE; GENETIC ASSOCIATION; HLA DPB1 GENE; HLA DRB1 GENE; HUMAN; INTERSTITIAL LUNG DISEASE; INTRACELLULAR SIGNALING; IRAK1 GENE; LUNG ALVEOLUS EPITHELIUM; NONHUMAN; PATHOGENESIS; STAT4 GENE; SYSTEMIC SCLEROSIS; TBX21 GENE; WNT SIGNALING PATHWAY; GENETIC PREDISPOSITION; GENETICS; PATHOLOGY; PHYSIOLOGY; REVIEW;

BETA CATENIN; EPIGENOMICS; GENETIC PREDISPOSITION TO DISEASE; HLA-D ANTIGENS; HUMANS; LUNG DISEASES, INTERSTITIAL; SCLERODERMA, SYSTEMIC; THROMBIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 84893674726     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-014-0411-1     Document Type: Article

References (74)

1. Marut W, Kavian N, Servettaz A, et al. Amelioration of systemic fibrosis in mice by angiotensin II receptor blockade. Arthritis Rheum. 2013;65:1367-77.
2. Jimenez SA, Hitraya E, Varga J. Pathogenesis of scleroderma. Collagen. Rheum Dis Clin N Am. 1996;22:647-74.
3. Silver RM, Wells AU. Histopathology and bronchoalveolar lavage. Rheumatology. 2008;47:62-4.
4. Li M, Krishnaveni MS, Li C, et al. Epithelium-specific deletion of TGF-β receptor type II protects mice from bleomycin-induced pulmonary fibrosis. J Clin Invest. 2014;121(1):277-87.
5. Homer RJ, Herzog EL. Recent advances in pulmonary fibrosis: implications for scleroderma. Curr Opin Rheumatol. 2010;22:683-9.
6. Wei J, Bhattacharyya S, Tourtellotte WG, Varga J. Fibrosis in systemic sclerosis: emerging concepts and implications for targeted therapy. Autoimmun Rev. 2011;10:267-75. This summarizes the molecular and cellular pathways leading to SSc-fibrosis.
7. Gilbane AJ, Denton CP, Holmes AM. Scleroderma pathogenesis: a pivotal role for fibroblasts as effector cells. Arthritis Res Ther. 2013;15:215.
8. Willis BC, Borok Z. TGF-b-induced EMT: mechanisms and implications for fibrotic lung disease. Am J Physiol Lung Cell Mol Physiol. 2007;293:525-34.
9. Hamaguchi Y. Autoantibody profiles in systemic sclerosis: predictive value for clinical evaluation and prognosis. J Dermatol. 2010;37:42-53.
10. Carmona FD, Cénit MC, Diaz-Gallo LM, Broen JC, et al. New insight on the Xq28 association with systemic sclerosis. Ann Rheum Dis. 2013;72:2032-8.
11. Pandit KV, Milosevic J, Kaminski N. MicroRNAs in idiopathic pulmonary fibrosis. Transl Res. 2011;157:191-9.
12. Meneghin A, Hogaboam CM. Infectious disease, the innate immune response, and fibrosis. J Clin Invest. 2007;117:530-8.
13. Gabrielli A, Svegliati S, Moroncini G, et al. Oxidative stress and the pathogenesis of scleroderma: the Murrell's hypothesis revisited. Semin Immunopathol. 2008;30:329-37.
14. Gabrielli A, Svegliati S, Moroncini G, Amico D. New insights into the role of oxidative stress in scleroderma fibrosis. Open Rheumatol J. 2012;6:87-95.
15. Chambers RC. The role of coagulation cascade proteases in lung repair and fibrosis. Eur Respir J. 2003;22:33-5.
16. Hant FN, Ludwicka-Bradley A, Wang HJ, et al. Surfactant protein D and KL-6 as serum biomarkers of interstitial lung disease in patients with scleroderma. J Rheumatol. 2009;36:773-80.
17. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119:1420-8.
18. Rocka JR, Barkauskasb CE, Cronceb MJ, et al. Multiple stromal populations contribute to pulmonary fibrosis without evidence for epithelial to mesenchymal transition. Proc Natl Acad Sci U S A. 2011;108:1475-83.
19. Kim KK, Kugler MC, Wolters PJ, et al. Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix. Proc Natl Acad Sci U S A. 2006;103:13180-5.
20. Hashimoto N, Jin H, Liu T, et al. Bone marrow-derived progenitor cells in pulmonary fibrosis. J Clin Invest. 2004;113:243-52.
21. Noble PW. Epithelial fibroblast triggering and interactions in pulmonary fibrosis. Eur Respir Rev. 2008;17:123-9.
22. Horowitz JC, Rogers DS, Sharma V, et al. Combinatorial activation of FAK and AKT by transforming growth factor-β1 confers an anoikis-resistant phenotype to myofibroblasts. Cell Signal. 2007;19:761-71.
23. Zhang H-Y, Phan SH. Inhibition of myofibroblasts apoptosis by transforming growth factor β1. Am J Respir Cell Mol Biol. 1999;21:658-65.
24. Moodley YP, Misso NL, Scaffidi AK, et al. Inverse effects of interleukin-6 on apoptosis of fibroblasts from pulmonary fibrosis and normal lungs. Am J Respir Cell Mol Biol. 2003;29:490-8.
25. Ajayi IO, Sisson TH, Higgins PD, et al. X-linked inhibitor of apoptosis regulates lung fibroblast resistance to Fas-mediated apoptosis. Am J Respir Cell Mol Biol. 2013;49:86-95.
26. Huang SK, Scruggs AM, Donaghy J, et al. Histone modifications are responsible for decreased Fas expression and apoptosis resistance in fibrotic lung fibroblasts. Cell Death Dis. 2013;4:621. doi: 10.1038/cddis.2013.146.
27. Hampel B, Malisan F, Niederegger H, et al. Differential regulation of apoptotic cell death in senescent human cells. Exp Gerontol. 2004;39:1713-21.
28. Kitani A, Fuss I, Nakamura K, et al. Transforming growth factor (TGF)-β1-producing regulatory T cells induce Smad-mediated interleukin 10 secretion that facilitates coordinated immunoregulatory activity and amelioration of TGF-β1-mediated fibrosis. J Exp Med. 2003;198:1179-88.
29. Sime PJ, O'Reilly KMA. Fibrosis of the lung and other tissues: new concepts in pathogenesis and treatment. Clin Immunol. 2001;99:308-19.
30. Khalil N, Bereznay O, Sporn M, Greenberg AH. Macrophage production of transforming growth factor beta and fibroblast collagen synthesis in chronic pulmonary inflammation. J Exp Med. 1989;70:727-37.
31. Letterio JJ, Roberts AB. Regulation of immune responses by TGF-β. Annu Rev Immunol. 1998;16:137-61.
32. Deng X, Mercer PF, Scotton CJ, Gilchrist A, Chambers RC. Thrombin induces fibroblast CCL2/JE production and release via coupling of PAR1 to Galphaq and cooperation between ERK1/2 and Rho kinase signaling pathways. Mol Biol Cell. 2008;19:2520-33.
33. Bogatkevich GS, Highland KB, Akter T, et al. Inhibition of thrombin as a novel strategy in the treatment of scleroderma-associated interstitial lung disease. Edited by Radstake T. InTech. Croatia 2012:131-48. This paper provides evidence for a promising therapeutic strategy: use of thrombin inhibitor in the treatment of murine lung fibrosis.
34. Ohba T, McDonald JK, Silver RM, et al. Scleroderma bronchoalveolar lavage fluid contains thrombin, a mediator of human lung fibroblast proliferation via induction of platelet-derived growth factor alpha-receptor. Am J Respir Cell Mol Biol. 1994;10:405-12.
35. Hernández-Rodríguez NA, Cambrey AD, Harrison NK, et al. Role of thrombin in pulmonary fibrosis. Lancet. 1995;346:1071-3.
36. Howell DCJ, Johns RH, Lasky JA, et al. Absence of protease-activated receptor-1 signaling affords protection from bleomycin-induced lung inflammation and fibrosis. Am J Pathol. 2005;166:1353-65.
37. Bogatkevich GS, Gustilo E, Oates J, et al. Distinct PKC isoforms mediate cell survival and DNA synthesis in thrombin-induced myofibroblasts. Am J Physiol Lung Cell Mol Physiol. 2005;288:190-201.
38. Bogatkevich GS, Tourkina E, Silver RM, Ludwicka-Bradley A. Thrombin differentiates normal lung fibroblast to a myofibroblast phenotype via proteolytically activated receptor-1 and protein kinase C-dependent pathway. J Biol Chem. 2001;276:45184-92.
39. Gray AJ, Bishop JE, Reeves JT, Laurent GJ. A alpha and B beta chains of fibrinogen stimulate proliferation of human fibroblasts. J Cell Sci. 1993;104:409-13.
40. Bachhuber BG, Sarembock IJ, Gimple LW, Owens GK. alpha-Thrombin induces transforming growth factor-beta1 mRNA and protein in cultured vascular smooth muscle cells via a proteolytically activated receptor. J Vasc Res. 1997;34:41-8.
41. Chambers RC, Leoni P, Blanc-Brude OP, Wembridge DE, Laurent GJ. Thrombin is a potent inducer of connective tissue growth factor production via proteolytic activation of protease-activated receptor-1. J Biol Chem. 2000;275:35584-91.
42. Bogatkevich GS, Ludwicka-Bradley A, Nietert PJ, Silver RM. Scleroderma lung fibroblasts: contractility and connective tissue growth factor. Edited by Gabbiani G, Chaponnier C, Desmouliere A. Texas: Landes. Bioscience 2006:25-31.
43. Tourkina E, Hoffman S, Fenton JW, Lipsitz S, et al. Depletion of protein kinase Cε in normal and scleroderma lung fibroblasts has opposite effects on tenascin expression. Arthritis Rheum. 2001;44:1370-81.
44. Chambers RC, Dabbagh K, McAnulty RJ, et al. Thrombin stimulates fibroblast procollagen production via proteolytic activation of protease-activated receptor 1. Biochem J. 1998;333:121-7.
45. Armstrong MT, Fenton 2nd JW, Andersen TT, Armstrong PB. Thrombin stimulation of matrix fibronectin. J Cell Physiol. 1996;166:112-20.
46. Howell DC, Laurent GJ, Chambers RC. Role of thrombin and its major cellular receptor, protease-activated receptor-1, in pulmonary fibrosis. Biochem Soc Trans. 2002;30:211-6.
47. Chambers RC. Procoagulant signalling mechanisms in lung inflammation and fibrosis: novel opportunities for pharmacological intervention? Br J Pharmacol. 2008;153:367-78.
48. Bogatkevich GS, Ludwicka-Bradley A, Silver RM. Dabigatran, a direct thrombin inhibitor, blocks differentiation of normal fibroblasts to a myofibroblast phenotype and demonstrates anti-fibrotic effects on scleroderma lung fibroblasts. Arthritis Rheum. 2009;60:3455-64.
49. Bogatkevich GS, Ludwicka-Bradley A, Nietert PJ, et al. Antiinflammatory and antifibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease. Arthritis Rheum. 2011;63:1416-25.
50. Königshoff M, Kramer M, Balsara N, Wilhelm J, et al. WNT1-inducible signaling protein-1 mediates pulmonary fibrosis in mice and is upregulated in humans with idiopathic pulmonary fibrosis. J Clin Invest. 2009;119:772-87.
51. Chilosi M, Poletti V, Zamò A, et al. Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis. Am J Pathol. 2003;162:1495-502.
52. Gordon MD, Nusse R. Wnt signaling: multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem. 2006;281:22429-33.
53. Shi-Wen X, Chen Y, Denton CP, et al. Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell. 2004;15:2707-19.
54. Moinzadeh P, Krieg T, Hellmich M, et al. Elevated MMP-7 levels in patients with systemic sclerosis: correlation with pulmonary involvement. Exp Dermatol. 2011;20:770-3.
55. Wei J, Melichian D, Komura K, et al. Canonical Wnt signaling induces skin fibrosis and subcutaneous lipoatrophy, a novel mouse model for scleroderma. Arthritis Rheum. 2011;63:1707-17.
56. Schneider AJ, Vezina CM, Richard E, et al. TCDD inhibition of canonical Wnt signaling disrupts prostatic bud formation in mouse urogenital sinus. Toxicol Sci. 2013;133:42-53.
57. Arnett FC, Cho M, Chatterjee S, et al. Familial occurrence frequencies and relative risks for systemic sclerosis (scleroderma) in three United States cohorts. Arthritis Rheum. 2001;44:1359-62.
58. Haustein U-F. Systemic sclerosis - an update. Lab Med. 2011;42:562-72.
59. Laing TJ, Gillespie BW, Toth MB, et al. Racial differences in scleroderma among women in Michigan. Arthritis Rheum. 1997;40:734-42.
60. Silver RM, Bogatkevich G, Tourkina E, et al. Racial differences between blacks and whites with systemic sclerosis. Curr Opin Rheumatol. 2012;24:642-8. This article provides evidence of correlation between race-dependent predisposition to fibrosis and biological variable factors.
61. Bogatkevich GS, Ludwicka-Bradley A, Highland KB, et al. Impairment of the antifibrotic effect of hepatocyte growth factor in lung fibroblasts from African Americans: possible role in systemic sclerosis. Arthritis Rheum. 2007;56:2432-42.
62. Gelber AC, Manno RL, Shah AA, et al. Race and association with disease manifestations and mortality in scleroderma: a 20-year experience at the Johns Hopkins Scleroderma Center and review of the literature. Medicine (Baltimore). 2013;92:191-205.
63. Steen V, Domsic RT, Lucas M, et al. A clinical and serologic comparison of African American and Caucasian patients with systemic sclerosis. Arthritis Rheum. 2012;64:2986-94.
64. Bogatkevich GS, Highland KB, Akter T, Silver RM. The PPARγ agonist rosiglitazone is antifibrotic for scleroderma lung fibroblasts: mechanisms of action and differential racial effects. Pulm Med. 2012;2012:545172. doi: 10.1155/2012/545172. This article provides functional evidence of race-based transcriptional factor over-activation and promising treatment for SSc-ILD on that basis.
65. Vargas-Alarcón G, Granados J, Ibañez de Kasep G, et al. Association of HLA-DR5 (DR11) with systemic sclerosis (scleroderma) in Mexican patients. Clin Exp Rheumatol. 1995;13:11-6.
66. Arnett FC. HLA and autoimmunity in scleroderma (systemic sclerosis). Int Rev Immunol. 1995;12:107-28.
67. Reveille JD. Molecular genetics of systemic sclerosis. Curr Opin Rheumatol. 1993;5:753-9.
68. Takeuchi F, Kuwata S, Nakano K, et al. Association of TAP1 and TAP2 with systemic sclerosis in Japanese. Clin Exp Rheumatol. 1996;14:513-21.
69. Luo Y, Wang Y, Wang Q, Xiao R, Lu Q. Systemic sclerosis: genetics and epigenetics. J Autoimmun. 2013;41:161-7.
70. Morel PA, Chang HJ, Wilson JW, et al. Severe systemic sclerosis with anti-topoisomerase I antibodies is associated with an HLA-DRw11 allele. Hum Immunol. 1994;40:101-10.
71. Romano E, Manetti M, Guiducci S, et al. The genetics of systemic sclerosis: an update. Clin Exp Rheumatol. 2011;29:75-86.
72. Wang Y, Fan PS, Kahaleh B. Association between enhanced type I collagen expression and epigenetic repression of the FLI1 gene in scleroderma fibroblasts. Arthritis Rheum. 2006;54:2271-9.
73. Makino K, Jinnin M, Hirano A, et al. The downregulation of microRNA let-7a contributes to the excessive expression of type I collagen in systemic and localized scleroderma. Immunology. 2013;190:3905-15.
74. Liu G, Friggeri A, Yang Y, et al. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med. 2010;207:1589-97.